Asgard Therapeutics is a startup based in Sweden, most recent round Series A, 2 tracked investors.
Based in Sweden, Asgard Therapeutics is a startup founded in 2018. Its most recent tracked round is Series A. Brouky records 2 investors associated with the company.
Asgard Therapeutics is a Swedish biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, developing gene therapies that reprogram tumor cells into antigen-presenting dendritic cells to trigger personalized immune responses against cancers.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.